Research

Metabolic adaptation

Retatrutide achieves an 82.4% relative reduction in hepatic fat and normalizes liver fat in 86% of patients.

Retatrutide may be beneficial for patients with fatty liver disease.

StrongSupportsmedium confidence
Retatrutide demonstrates potent efficacy in resolving metabolic dysfunction-associated steatotic liver disease, achieving an 82.4% relative reduction in hepatic fat and normalization of liver fat in 86% of patients.
Ashwin A. Pillai et al. · Cardiology in Review · 2026

Why this rating

Based on Phase 2 clinical data from a controlled study.

Source

Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review

Ashwin A. Pillai et al. · Cardiology in Review · 2026

DOI 10.1097/crd.0000000000001310

review
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →